The RadioVal project which is co-funded under Horizon Europe has started in October 2022 and runs until September 2025, coordinated by the University of Barcelona in Spain. Overall, 16 partners from all around the world are working together for the success of this project.
RadioVal is a multidisciplinary and multicontinental project aiming to clinically validate an artificial intelligence solution for the prediction of patient-specific response to neoadjuvant chemotherapy in breast cancer. The validation takes place in eight clinical centres across Europe, South America, North Africa and Eurasia to ensure that the validated AI tool is tested in diverse social and clinical settings.
As the main result of RadioVal, the validated AI tool will be able to support clinicians in selecting the patients that are most likely to respond to neoadjuvant chemotherapy and by that unnecessary chemotherapy treatments and side effects can be reduced.